Zika Virus Liquid Biopsy: A Dendritic Ru(bpy)$_3^{2+}$-Polymer-Amplified ECL Diagnosis Strategy Using a Drop of Blood

Yuhui Liao,†‡∥§ Qingqin Tan,†∥§ Bin Li,†∥§ Jingyan Lin,∥§ Zhaoyan Zhao,‡∥§ Zhijian Fan,†‡∥ Huaping Deng‡∥ Yang Yang,# Jingyan Lin,# Zhaoyan Zhao,‡∥§ Jia Chen,‡∥ Jingyan Lin,# Jingyan Lin,# Zhaoyan Zhao,‡∥§ Jia Chen,‡∥ Jingyan Lin,# Zhaoyan Zhao,‡∥§ Jia Chen,‡∥ Jingyan Lin,# Zhaoyan Zhao,‡∥§ Jia Chen,‡∥ Jingyan Lin,# Zhaoyan Zhao,‡∥§ Jia Chen,‡∥ Jingyan Lin,# Zhaoyan Zhao,‡∥§ Jia Chen,‡∥ Jingyan Lin,# Zhaoyan Zhao,‡∥§ Jia Chen,‡∥ Jingyan Lin,# Zhaoyan Zhao,‡∥§ Jia Chen,‡∥ Jingyan Lin,# Zhaoyan Zhao,‡∥§ Jia Chen,‡∥ Jingyan Lin,# Zhaoyan Zhao,‡∥§ Jia Chen,‡∥ Jingyan Lin,# Zhaoyan Zhao,‡∥§ Jia Chen,‡∥ Jingyan Lin,# Zhaoyan Zhao,‡∥§ Jia Chen,‡∥ Jingyan Lin,# Zhaoyan Zhao,‡∥§ Jia Chen,‡∥ Jingyan Lin,# Zhaoyan Zhao,‡∥§ Jia Chen,‡∥ Jingyan Lin,# Zhaoyan Zhao,‡∥§ Jia Chen,‡∥ Jingyan Lin,# Zhaoyan Zhao,‡∥§ Jia Chen,‡∥ Jingyan Lin,# Zhaoyan Zhao,‡∥§ Jia Chen,‡∥ Qingyin Tan,

†Program of Infection and Immunity, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhongshan School of Medicine, Sun Yat-sen University, Guangdong 510120, China
‡Department of Internal Medicine, Guangzhou Women and Children’s Medical Center, Zhongshan School of Medicine, Sun Yat-sen University, Guangdong 510120, China
§Sino-French Hoffmann Institute of Immunology, College of Basic Medical Science, Guangzhou Medical University, Guangzhou 510000, China
∥Key Laboratory of Tropical Diseases Control, Ministry of Education, Sun Yat-sen University, Guangdong 510120, China
†The First Hospital of Jilin University, Changchun 130021, China
#Shenzhen Key Laboratory of Pathogen and Immunity, State Key Discipline of Infectious Disease, Shenzhen Third People’s Hospital, Shenzhen 518112, China

ABSTRACT: Zika virus (ZIKV) is a mosquito-borne flavivirus that leads to devastating consequences for fetal development. However, accurate diagnosis of ZIKV is made difficult by the fact that most infected patients are asymptomatic or present with symptoms similar to those of other febrile illnesses. Thus, the development of a simple, accurate, highly sensitive, and reliable method for the biomedical analysis and diagnosis of ZIKV is needed. Herein, a novel ZIKV liquid biopsy system was constructed via a dendritic Ru(bpy)$_3^{2+}$-polymer-amplified electro-chemiluminescence (ECL) strategy. This system accomplished amplification-free analysis of ZIKV using a drop of blood, and simultaneously achieved a high sensitivity of 500 copies and superior specificity. This strategy adopted the humoral biomarker as the diagnostic index, which greatly simplified the analysis process, and established a nondestructive detection mode. Furthermore, the performance index for biomedical analysis of clinical ZIKV samples was investigated, and the results indicated that the dendritic Ru(bpy)$_3^{2+}$-polymer-amplified ECL strategy reliably responded to ZIKV from the body fluid (blood, saliva, and urine). Hence, this system suitably met the strict clinical requirements for ZIKV detection and thus has the potential to serve as a new paradigm for the biomedical analysis and diagnosis of ZIKV.

INTRODUCTION

The Zika virus (ZIKV) is an Aedes mosquito-borne flavivirus that could produce devastating consequences for the process of fetal development. Furthermore, ZIKV has been declared a public health emergency of international concern by the World Health Organization (WHO) because of the large-scale outbreak of the virus in the Americas. ZIKV mainly spreads via infected mosquito bite, but can also be transmitted by mother-to-fetus transmission, sexual contact, or blood transfusion. Additionally, it has been indicated that the infection of ZIKV was the main cause of Guillain-Barré syndrome, congenital microcephaly, and neurological defects in newborns. Thus, the development of a simple, accurate, highly sensitive, and reliable method for the biomedical analysis and diagnosis of ZIKV would be of great significance for the prevention and control of ZIKV. However, biomedical analysis and accurate diagnosis of ZIKV are made difficult by the fact that most infected patients are asymptomatic or present symptoms similar to those of other febrile illnesses.

The existing immunoassays for ZIKV detection, such as the enzyme-linked immunosorbent assay (ELISA), provide an inexpensive and instrumentless approach, but their poor sensitivity and specificity limited the application of these immunoassays applied to the clinical detection and diagnosis of ZIKV. In particular, the antibody used in the immunoassay for ZIKV detection would also respond to homologous flaviviruses, such as Dengue virus. Thus, the specificity of immunoassays cannot meet the requirements for the accurate detection and early diagnosis of ZIKV. Conversely, the enzymatic amplification-based detection
assays, such as reverse-transcription polymerase chain reaction (RT-PCR),\textsuperscript{25,26} and nucleic acid sequence-based amplification (NASBA),\textsuperscript{27,28} are endowed with the properties of high sensitivity and desirable specificity. In particular, the PCR-based assays are considered the gold standard for ZIKV detection. However, the labor-intensive sample pretreatment steps, expensive equipment, centralized laboratory facilities, and trained personnel required by PCR greatly reduced the popularization rate of its clinical application.\textsuperscript{29,30} Therefore, it is of significance to develop a novel method for biomedical analysis and diagnosis of ZIKV.

In recent years, the rapid developments in biomedical analysis and analytical chemistry have led to the emergence of many new detection platforms.\textsuperscript{31–34} This advancement inspired us to construct a new methodology for biomedical analysis and diagnosis of ZIKV. Herein, a novel ZIKV liquid biopsy system was constructed by integrating a dendritic Ru(bpy)\textsubscript{3}\textsuperscript{2+}-polymer-amplified electro-chemiluminescence (ECL) strategy as an effective signal giving-out pattern. This system accomplished amplification-free analysis of ZIKV using a drop of blood, and simultaneously achieved a high sensitivity of 500 copies and desirable specificity. This strategy adopted the humoral biomarker as the diagnostic index, which greatly simplified the biomedical analysis process, and established a nondestructive detection mode. Furthermore, we investigated the performance index for the biomedical analysis of clinical ZIKV samples, and the results indicated that the Ru(bpy)\textsubscript{3}\textsuperscript{2+}-polymer-amplified ECL strategy steadily responded to ZIKV from the body fluid (blood, saliva, and urine). Hence, this system suitably met the strict clinical requirements for ZIKV detection and thus has the potential to serve as a new paradigm for the biomedical analysis and diagnosis of ZIKV.

■ RESULTS AND DISCUSSION

Design of a Dendritic Ru(bpy)\textsubscript{3}\textsuperscript{2+}-Polymer-Amplified ECL Assay. The constructed ZIKV liquid biopsy system was composed of the sample pretreatment, RNA enrichment, and ECL signal readout steps (Figure 1). First, ZIKV samples from body fluids (blood, saliva, and urine) were pretreated by dissociation and magnetic bead enrichment. Biomedical analysis and diagnosis of ZIKV via body fluid samples can provide a nondestructive detection mode that greatly simplifies the analysis process and alleviates the damage to the patients. Subsequently, the RNA of ZIKV was immobilized on magnetic beads by capture probe. The magnetic bead enrichment step can concentrate low-concentration ZIKV RNA from ZIKV samples and increase the specificity via the recognition induced by the capture probe, which immobilized the ZIKV RNA on the magnetic beads. Finally, the RNA captured by the magnetic beads was recognized by the dendritic Ru(bpy)\textsubscript{3}\textsuperscript{2+}-polymer-amplified ECL probe after the washing process. The amplified probe provides a stable, intense response signal for ZIKV, and serves as the foundation of the high sensitivity of the method. The distinguishable ECL signals were then detected by an ECL instrument.

The construction of the dendritic Ru(bpy)\textsubscript{3}\textsuperscript{2+}-polymer-amplified ECL probe for ZIKV comprises the synthesis of Ru(bpy)\textsubscript{3}\textsuperscript{2+} and probe assembly. The synthetic route and characterization of activated Ru(bpy)\textsubscript{3}\textsuperscript{2+} are shown in Figure 2A (the complete synthetic process is outlined in section 1.1 of the Supporting Information, Figures S1 and S2). The assembly of the dendritic Ru(bpy)\textsubscript{3}\textsuperscript{2+}-polymer-amplified ECL probe (Figure 2B) was initiated via the sulphydryl and double-bond interaction between the dendritic polymer and the DNA recognition domain (the structural formula of the dendritic polymer and the reaction process are presented in Figures S3 and S4). In this structure, the amino groups of the dendritic polymer provided the conjugation site for carboxyl-activated Ru(bpy)\textsubscript{3}\textsuperscript{2+} (the complete synthetic route for the dendritic Ru(bpy)\textsubscript{3}\textsuperscript{2+}-polymer-amplified ECL probe is outlined in section 1.2 of the Supporting Information). The differences in properties between the dendritic Ru(bpy)\textsubscript{3}\textsuperscript{2+}-polymer and Ru(bpy)\textsubscript{3}\textsuperscript{2+} were compared, and are listed below.

The photograph of the dendritic Ru(bpy)\textsubscript{3}\textsuperscript{2+}-polymer and Ru(bpy)\textsubscript{3}\textsuperscript{2+} in Figure 2C indicated that the dendritic Ru(bpy)\textsubscript{3}\textsuperscript{2+}-polymer exhibited a light-brown color, and that Ru(bpy)\textsubscript{3}\textsuperscript{2+} was yellow. This presents the obvious distinctions between the dendritic Ru(bpy)\textsubscript{3}\textsuperscript{2+}-polymer and Ru(bpy)\textsubscript{3}\textsuperscript{2+} in character. The spectral characterization results (Figure 2C) reveal that the dendritic Ru(bpy)\textsubscript{3}\textsuperscript{2+}-polymer possesses excitation and emission wavelengths identical to those of Ru(bpy)\textsubscript{3}\textsuperscript{2+} (Figures S5 and S6). The maximum absorption peak of the dendritic Ru(bpy)\textsubscript{3}\textsuperscript{2+}-polymer appeared at 450 nm, whereas the emission peak appeared at 660 nm. These results indicate that the synthetic route for the dendritic Ru(bpy)\textsubscript{3}\textsuperscript{2+}-polymer is feasible, and that Ru(bpy)\textsubscript{3}\textsuperscript{2+} and the dendritic polymer can be connected. Meanwhile, we evaluated the junction between the dendritic Ru(bpy)\textsubscript{3}\textsuperscript{2+}-polymer and the specific recognition domains to confirm the feasibility of the assembly step for the dendritic Ru(bpy)\textsubscript{3}\textsuperscript{2+}-polymer-amplified ECL probe. Specifically, the dendritic Ru(bpy)\textsubscript{3}\textsuperscript{2+}-polymer-amplified ECL probe was characterized on the basis of its absorption spectrum. The results in Figure 2D indicate that absorption peaks simultaneously appeared at 260 nm (DNA peak) and 450 nm (Ru(bpy)\textsubscript{3}\textsuperscript{2+} peak) after the dendritic...
The absorption and amount of Ru(bpy)$_3$ of the dendritic Ru(bpy)$_3$ addition, we also investigated the stability of the ECL intensity evaluated by simultaneously recording the fluorescence spectra of the dendritic Ru(bpy)$_3$ DRP represents the dendritic Ru(bpy)$_3$ peak of the dendritic Ru(bpy)$_3$ emission peak was at 660 nm. (D) Absorption spectrum of the dendritic Ru(bpy)$_3$ peaks simultaneously appeared at 260 and 450 nm after the dendritic polyamino process and the complete structure of the dendritic Ru(bpy)$_3$-polymer are shown in section 1.1 of the Supporting Information. (C) Excitation and emission of the dendritic Ru(bpy)$_3$-polymer. The concentrations of the solutions were identical. 2+-polymer was linked with nucleic acids. The details of the activation processes are provided in Figures S7 and S8. Both the absorption and fluorescence spectra of the dendritic Ru(bpy)$_3$-polymer were recorded to calculate the extent of labeling via comparison with the standard curves (Figures S7 and S8). Both the absorption and fluorescence spectra indicated that a labeling rate of approximately 50% Ru(bpy)$_3$ on the dendritic polymer was achieved. The particle size and ζ potential are listed in Figures S9 and S10. These results also preliminarily verified the feasibility of the synthetic route for the dendritic Ru(bpy)$_3$-polymer. In addition, we also investigated the stability of the ECL intensity of the dendritic Ru(bpy)$_3$-polymer probe. The ECL signal of the dendritic Ru(bpy)$_3$-polymer probe was detected at different time points (an excess of the reactant, terephthalic acid, was used). The results in Figure S11 show that the dendritic Ru(bpy)$_3$-polymer probe provided an intense ECL signal. Additionally, the ECL intensity of the dendritic Ru(bpy)$_3$-polymer probe remained stable for different times from 10 to 60 min, revealing the stability of the luminescence from the dendritic Ru(bpy)$_3$-polymer probe.

**Target Sequence Design Strategy.** ZIKV belongs to a series of flaviviruses that are homologous in genetic information. Thus, the existing methods based on immuno-assays cannot effectively differentiate different flaviviruses, especially the dengue virus and ZIKV. In this work, we designed the conserved sequence from the ZIKV NS1 gene. The genomes of ZIKV strains used in the present study were downloaded from the National Center for Biotechnology Information (NCBI) database (http://www.ncbi.nlm.nih.gov/genome/viruses/variation/Zika/), and aligned using MEGA 7. Conserved ZIKV-specific sequences that were divergent from other flaviviruses were identified. The alignment results of some ZIKV strains and other related flavivirus strains are shown in Figure 3. For the ZIKV strains, the Asian lineage is in purple, while the African lineage is in red. Herein, we verified the specificity of the ZIKV liquid biopsy system for flaviviruses with the designed sequence. The results in Figure 4A indicated that the ZIKV liquid biopsy system could specifically respond to ZIKV, and that the other flavivirus group did not provide an ECL signal that could differentiate them from the control group. Therefore, the specificity of the ZIKV liquid biopsy system obtained a better proof. Additionally, the sequence was distinctive from those of other flaviviruses. The results proved that this system could respond to different ZIKV strains (Figure 4B). Five ZIKV strains were simultaneously detected, and stable and differentiable ECL signals were acquired. Thus, the ZIKV liquid biopsy system provided outstanding specificity and desirable
ZIKV recognition ability. These performance indexes indicate that this system can suitably meet the clinical requirements for a ZIKV liquid biopsy method.

Performance Index of the Dendritic Ru(bpy)$_3^{2+}$-Polymer-Amplified ECL Strategy. Performance indexes of the dendritic Ru(bpy)$_3^{2+}$-polymer-amplified ECL strategy were evaluated in this section. First, we evaluated the sensitivity of the dendritic Ru(bpy)$_3^{2+}$-polymer. The results in Figure 4C revealed that the dendritic Ru(bpy)$_3^{2+}$-polymer reached a high sensitivity of 500 copies. Therefore, the dendritic Ru(bpy)$_3^{2+}$-polymer provided an excellent luminescence signal over a wide response range, providing a foundation for the clinical detection and diagnosis of ZIKV. We also investigated the specificity of the dendritic Ru(bpy)$_3^{2+}$-polymer-amplified ECL assay by comparing the ECL intensity produced in response to the specific sequence and random sequences (listed in Table S2). The results in Figure 4D indicated that only the specific ZIKV sequence resulted in intense ECL; the random sequences showed essentially the same ECL intensity as that of the control group. This result verifies the specificity of the polymer-amplified ECL assay for nucleic acids.

Verification of the Zika Virus Liquid Biopsy System for Infected Mice. In this section, we constructed a mouse model of the ZIKV infection. Blood and urine samples were collected and detected for the preliminary verifications of the ZIKV liquid biopsy system in clinical sample detection. However, the detection of saliva samples was not executed because saliva samples were very difficult to collect. We first detected blood samples from the mice infected with ZIKV. The blood samples were treated with a 5-fold volume of sodium dodecyl sulfate (SDS) buffer. The results in Figure 5A revealed that the ZIKV liquid biopsy system achieved a high detection ratio of 90%. Then, the urine samples from the infected mice were collected by a simple device constructed by our group (Figure 5B). Subsequently, the solution of ZIKV was processed by magnetic bead enrichment. Finally, the response signal was obtained by the dendritic Ru(bpy)$_3^{2+}$-polymer probe. The results in Figure 5C indicated that the ZIKV liquid biopsy system could stably respond to all the ZIKV samples from the urine of infected mice. Stable signals were acquired from most of the urine samples. Thus, it can be proven that this ZIKV liquid biopsy system possesses the ability to detect ZIKV from the urine and blood of the mice that were artificially infected with ZIKV. The results in Figure 5D indicated that the ZIKV liquid biopsy system could specifically respond to ZIKV in blood and urine, and that the other flavivirus groups did not provide an ECL signal that could differentiate from the control group. Therefore, the specificity of the ZIKV liquid biopsy system for body fluid samples was proven.

Instance for Biomedical Analysis of ZIKV from Clinical Samples. Previous studies have established that ZIKV can be detected in body fluids (blood, saliva, and urine) of infected patients. In symptomatic patients, viremia ranges from $7.28 \times 10^6$ to $9.3 \times 10^8$ copies/mL, and in asymptomatic patients, it ranges from $2.5 \times 10^3$ to $8 \times 10^6$ copies/mL. These results inspired us to construct a novel detection mode (ZIKV liquid biopsy system) that adopted the humoral biomarker as the diagnostic index, which greatly simplified the biomedical analysis process, and established a non-destructive approach. For verification of whether this system can be applied to the clinical samples, the sensitivity of this ZIKV liquid biopsy system for blood samples was assessed, and the results are recorded in Figure 6A. The sensitivity of this system reached $10^3$ copies, indicating that it could detect the viral load in most ZIKV patients.
Moreover, we simulated spiked ZIKV samples by adding ZIKV to body fluids (blood, saliva, and urine). Specifically, $10^6$ ZIKV copies were added to the 120 samples from healthy adults. We proceeded to carry out stability estimations with the spiked ZIKV samples (50 blood samples, 50 saliva samples, and 20 urine samples). The results in Figure 6B−D indicate that the ZIKV in body fluids (blood, saliva, and urine) can be steadily detected by the ZIKV liquid biopsy system. This finding confirmed the performance of the ZIKV liquid biopsy system on clinical samples. In Figure 6, only 30 samples are listed; the remaining 90 samples are shown in Figures S12−S14. The positive rates achieved in spiked blood, saliva, and urine samples were 94%, 96%, and 90%, respectively. Thus, these results indicated that this system could be applied to the liquid biopsy of ZIKV samples. Although we intended to use the detection process for assessing clinical samples from patients who were infected with ZIKV to further evaluate the properties of the ZIKV liquid biopsy system, patients infected with ZIKV in China are very rare. We sought to collect body fluid samples from patients infected with ZIKV, but did not find them. Thus, this strategy remains to be examined by body fluid samples from patients infected with ZIKV. However, the spiked samples in blood, saliva, and urine confirmed the feasibility for clinical samples to some extent.

Comparisons with Existing ZIKV Detection Methods.

The existing ZIKV detection methodology focused on the biomarkers such as virus-specific antigens, immunoglobulins, antibodies, and viral nucleic acids. Herein, we systematically compared the performance of existing ZIKV detection methods and the ZIKV liquid biopsy system. As shown in Figure 7A, the ZIKV detection methods that hinged on quantitative information obtained from proteic biomarkers were mostly based on the immunoassay strategy42−45 (such as ELISA and immunochromatography) which could not differentiate ZIKV from the other homologous flaviviruses, such as the Dengue virus. The homology of flaviviruses greatly limits the application of ZIKV detection methods based on the immunoassay strategy to clinical analysis. In addition to this limitation, the main shortcomings of immunoassays for ZIKV

Figure 6. Biomedical analysis of ZIKV from clinical human body fluid samples and modeling samples. (A) Sensitivity of the ZIKV liquid biopsy system for blood samples. (B) Biomedical analysis of ZIKV in spiked blood samples. (C) Biomedical analysis of ZIKV in spiked urine samples. (D) Biomedical analysis of ZIKV in spiked saliva samples.

Figure 7. Performance comparison of existing ZIKV detection methods. (A) Performance of immunoassays for ZIKV detection. (B) Performance of nucleic-acid-based diagnostics for ZIKV detection. (C) Performance of the ZIKV liquid biopsy system.

1407
are the low sensitivity and the high costs of antibodies. Therefore, ZIKV detection methods based on viral nucleic acids \(^{46-51}\) (Figure 7B) provided superior alternative to immunoassays that could differentiate the other flaviviruses via sequence analysis and could provide improved specificity. Furthermore, the sensitivity and the whole costs were considerably improved. However, these methods require time-consuming, complex sample preparation and nucleic acid extraction procedures. The commercial kits of sample preparation and nucleic acid extraction procedures require more than 40 min and skilled technicians, and the subsequent PCR usually requires approximately 40 min. Thus, a whole PCR process for ZIKV detection took more than 80 min.

Compared with these methods, the ZIKV liquid biopsy system (Figure 7C) achieved a sensitivity that was slightly lower than the PCR and NASBA methods. However, the sensitivity is sufficient to meet the clinical needs for ZIKV liquid biopsy. Meanwhile, the process was substantially simplified because no amplification step is required by the ZIKV liquid biopsy system; only 40 min was required to analyze each sample. Furthermore, the ZIKV liquid biopsy system can differentiate ZIKV from other flaviviruses, and desirable specificity was obtained. The cost of the ZIKV liquid biopsy system was 25 Yuan RMB for one test (the details are listed in Table S3). This cost is much lower than those of an immunoassay and most of the nucleic acid-based diagnoses. In addition, direct comparison with existing techniques (immunoassay, PCR, NASBA) using commercial kits was performed under the same experimental conditions. The results and descriptions are detailed in the Supporting Information. In conclusion, this ZIKV liquid biopsy system suitably met the strict clinical requirements for ZIKV detection and thus has the potential to serve as a new paradigm for the biomedical analysis and diagnosis of ZIKV.

### CONCLUSIONS

A novel ZIKV liquid biopsy system was constructed by integrating a Ru(bpy)\(_{3}\)\(^{2+}\)-polymer-amplified ECL strategy as an effective signal giving-out pattern. The amplification-free analysis of ZIKV was performed using a drop of blood, and a high sensitivity of 500 copies and desirable specificity were simultaneously achieved. This strategy adopted the humoral biomarker as the diagnostic index, which greatly simplified the biomedical analysis process, and established a nondestructive detection mode. Furthermore, we investigated the performance index for the biomedical analysis of clinical ZIKV samples, and the results indicated that the Ru(bpy)\(_{3}\)\(^{2+}\)-polymer-amplified ECL strategy reliably responded to ZIKV in body fluids (blood, saliva, and urine). Hence, this system suitably met the strict clinical requirements for ZIKV liquid biopsy and thus has the potential to serve as a new paradigm for the biomedical analysis and diagnosis of ZIKV.

### EXPERIMENTAL SECTION

Reagents. All of the oligonucleotides and probes used in this paper were synthesized and purified by Invitrogen. cis-Bis(2,2’-bipyridine)dichlororuthenium(II), 2,2’-bipyridine-4, 4’-dicarboxylic acid, \(N,N’\)-dicyclohexylcarbodiimide (DCC), sodium borate, sodium hexafluorophosphate, \(N-(3-\text{(dimethylamino)propyl})-N’\)-ethylcarbodiimide hydrochloride (EDC), and \(N\)-hydroxy succinimide (NHS) were obtained from Alfa Aesar Co., Ltd. Streptavidin magnetic beads were synthesized by New England BioLabs. Diethylpyrocarbonate-treated (DEPC-treated) water and RNAse inhibitor were obtained from Takara Biotechnology (Dalian) Co., Ltd.

**Synthetic Routes for Ru(bpy)\(_{3}\)\(^{2+}\) and Dendritic Ru(bpy)\(_{3}\)\(^{2+}\)-Polymer.** The Ru(bpy)\(_{3}\)\(^{2+}\)-NHS ester was synthesized by the synthetic procedure for Ru(bpy)\(_{3}\)(dcbpy)(PF\(_{6}\)) and activation of the carboxyl group on Ru(bpy)\(_{3}\)\(^{2+}\). Ru(bpy)\(_{3}\)\(^{2+}\) was synthesized by refluxing cis-dichlorobis(2,2’-bipyridine)ruthenium(II) with an excess of the corresponding 2,2’-bipyridine-4,4’-dicarboxylic acid (1:1.2) in an ethanol/water (80%) mixture and incubating at 80 °C for one night. The solution was subsequently cooled and acidified (pH = 4.4) to crystallize out the unreacted 2,2’-bipyridine-4,4’-dicarboxylic acid. The sediment was washed and removed with a qualitative filter-paper-based suction filter. A precooled solution of sodium hexafluorophosphate (NaPF\(_{6}\)) was added to the resultant filtrate isolates of the ruthenium complexes as PF\(_{6}\) salts. The mixture was cooled with an ice-water mixture. Then, the crystal products were treated with the freeze-drying process to eliminate the influence of volatile solvents. At this point, the synthetic procedure for Ru(bpy)\(_{3}\)(dcbpy)(PF\(_{6}\)) was terminated.

The core of the dendrimer polymer was obtained from Sigma and then modified with amino acids via lipid reactions. The molecular ratio between maleimide-labeled DNA and the amino-labeled dendritic polymer was set to 10:1. A mixture of maleimide-labeled DNA and the amino-labeled dendritic polymer was incubated at 37 °C for 12 h. Then, the dissociated DNA was removed with an ultrafiltration device. The obtained products were mixed with carboxyl-activated Ru(bpy)\(_{3}\)\(^{2+}\) at a molecular ratio of 1:1000 and incubated at 37 °C for 12 h. The products were purified by sedimentation with precooled alcohol solution and centrifugation.

**Dissociation Process of ZIKV and Magnetic Beads Enrichment.** The ZIKV samples were separated with a commercial virus-lysis kit, the key constituent of which was SDS. To achieve a better separation effect, the solution could be heated to 60 °C for 5 min. A 10 μL portion of magnetic beads (1 mg/mL) labeled with capture probe was added to each sample for 10 min. Meanwhile, the mixture was processed by magnetic separation. The captured products were collected for later ECL steps.

**ECL Process.** The magnetic beads used in this assay were labeled with streptavidin and could recognize and bind biotin from the capture probe. The signal probe, composed of the dendritic Ru(bpy)\(_{3}\)\(^{2+}\)-polymer and recognition domain, was employed as the ECL-generating group. When the target is present, the capture probe and signal probe form the classic sandwich structure, which can be adapted to nucleic acid detection. The gradient cooling process was more effective. Eventually, the streptavidin magnetic beads captured the sandwich structure. After the washing steps, the ECL signal was detected in the presence of the co-reactant tripropylamine (TPA).

### ASSOCIATED CONTENT

#### Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acscentsci.8b00471.
Characterization of dendritic Ru(bpy)₃²⁺-polymer, biochemical analysis of ZIKV from clinical samples, and performance of the existing method for ZIKV detection (PDF)

AUTHOR INFORMATION

Corresponding Author
*E-mail: huangxie@mail.sysu.edu.cn. Phone: +8613694296389.

ORCID

Yuhui Liao: 0000-0003-4702-9516
Xi Huang: 0000-0002-4829-8390

Notes
The authors declare no competing financial interest. Safety statement: no unexpected or unusually high safety hazards were encountered.

ACKNOWLEDGMENTS

This work was supported by grants from the National Natural Science Foundation of China (31470877, 81261160323), the National Key Research and Development Program of China (2016YFC1200105), the National Science and Technology Key Projects for Major Infectious Diseases (2017ZX10003001 and 2013ZX10003001), the Science and Technology Planning Project of Guangzhou (201704020226, 2016A020205001, and 201604020006), and the Guangdong Natural Science Foundation (2015A030311009).

REFERENCES

(1) Pardi, N.; Hogan, M. J.; Pelc, R. S.; Muramatsu, H.; Andersen, H.; DeMaso, C. R.; Dowd, K. A.; Sutherland, L. L.; Searce, R. M.; Parks, R.; Wagner, W.; Granados, A.; Greenhouse, J.; Walker, M.; Willis, E.; Yu, J. S.; McGee, C. E.; Sempowski, G. D.; Mou, B. L.; Tam, Y. K.; Huang, Y.-J.; VanLandingham, D.; Holmes, V. M.; Balachandran, H.; Sahu, S.; Lifton, M.; Higgs, S.; Hensley, S. E.; Madden, T. D.; Hope, M. J.; Karkik, K.; Santra, S.; Graham, B. S.; Lewis, M. G.; Pierson, T. C.; Haynes, B. F.; Weissman, D. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 2017, 543, 248–252.

(2) Uraki, R.; Jurado, K. A.; Hwang, J.; Sjogren-Buck, K.; Horvath, T. L.; Iwasaki, A.; Fikrig, E. Fetal Growth Restriction Caused by Sexual Transmission of Zika Virus in Mice. J. Infect. Dis. 2017, 215, 1720–1724.

(3) Fauci, A. S.; Morens, D. M. Zika virus and birth defects—reviewing the evidence for causality. N. Engl. J. Med. 2016, 374, 1981–1987.

(4) Cogula, F. R.; Fernandes, I. R.; Russo, F. B.; Freitas, B. C.; Dias, J. L.; Guimarães, K. P.; Benazzato, C.; Almeida, N.; Pignatari, G. C.; Romero, S. The Brazilian Zika virus strain causes birth defects in experimental models. Nature 2016, 534, 267–271.

(5) Mlakar, J.; Korva, M.; Tul, N.; Popovic, M.; Poljsak-Prijatelj, M.; Mraz, J.; Kolenc, M.; Rus, K. R.; Vipotnik, T. V.; Vodusek, V. F.; Virak, J.; Pizem, J.; Petrovec, M.; Zupanc, T. A. Zika Virus Associated with Microcephaly. N. Engl. J. Med. 2016, 374 (10), 951–958.

(6) Rasmussen, S. A.; Jamieson, D. J.; Honein, M. A.; Petersen, L. R. Zika virus and birth defects—reviewing the evidence for causality. N. Engl. J. Med. 2016, 374, 1981–1987.

(7) Laranca, R. A.; Abbbink, P.; Peron, J. P. S.; Zanotto, P. M. d. A.; Iampietro, M. J.; Badamchizadeh, A.; Boyd, M.; Ng’ang’a, D.; Irilova, M.; Nitanyandam, R.; Mercado, N. B.; Li, Z.; Moseley, E. T.; Bricault, C. A.; Borducchi, E. N.; Giglio, P. B.; Jetton, D.; Neubauer, G.; Knolko, J. P.; Maxfield, L. F.; De La Barrera, R. A.; Jarman, R. G.; Bricault, C. A.; Borducchi, E. N.; Giglio, P. B.; Jetton, D.; Neubauer, G.; Knolko, J. P.; Maxfield, L. F.; De La Barrera, R. A.; Jarman, R. G.; Bricault, C. A.; Borducchi, E. N.; Giglio, P. B.; Jetton, D.; Neubauer, G.; Knolko, J. P.; Maxfield, L. F.; De La Barrera, R. A.; Jarman, R. G.; Bricault, C. A.; Borducchi, E. N.; Giglio, P. B.; Jetton, D.; Neubauer, G.; Knolko, J. P.; Maxfield, L. F.; De La Barrera, R. A.; Jarman, R. G.; Bricault, C. A.; Borducchi, E. N.; Giglio, P. B.; Jetton, D.; Neubauer, G.; Knolko, J. P.; Maxfield, L. F.; De La Barrera, R. A.; Jarman, R. G.; Bricault, C. A.; Borducchi, E. N.; Giglio, P. B.; Jetton, D.; Neubauer, G.; Knolko, J. P.; Maxfield, L. F.; De La Barrera, R. A.; Jarman, R. G.; Bricault, C. A.; Borducchi, E. N.; Giglio, P. B.; Jetton, D.; Neubauer, G.; Knolko, J. P.; Maxfield, L. F.; De La Barrera, R. A.; Jarman, R. G.; Bricault, C. A.; Borducchi, E. N.; Giglio, P. B.; Jetton, D.; Neubauer, G.; Knolko, J. P.; Maxfield, L. F.; De La Barrera, R. A.; Jarman, R. G.; Bricault, C. A.; Borducchi, E. N.; Giglio, P. B.; Jetton, D.; Neubauer, G.; Knolko, J. P.; Maxfield, L. F.; De La Barrera, R. A.; Jarman, R. G. Zika virus replication and fetal disease in mice. Nature 2016, 540, 443–447.

(8) Uraki, R.; Jurado, K. A.; Hwang, J.; Sjogren-Buck, K.; Horvath, T. L.; Iwasaki, A.; Fikrig, E. Fetal Growth Restriction Caused by Sexual Transmission of Zika Virus in Mice. J. Infect. Dis. 2017, 215, 1720–1724.

(9) Rasmussen, S. A.; Jamieson, D. J.; Honein, M. A.; Petersen, L. R. Zika virus and birth defects—reviewing the evidence for causality. N. Engl. J. Med. 2016, 374, 1981–1987.

(10) Fauci, A. S.; Morens, D. M. Zika virus in the Americas—yet another arbovirus threat. N. Engl. J. Med. 2016, 374, 601–604.

(11) Stephen, P.; Baz, M.; Boivin, G.; Lin, S. X. Structural Insight into Nss of Zika Virus Leading to the Discovery of MTase Inhibitors. J. Am. Chem. Soc. 2016, 138, 16212–16215.

(12) Dejucq-Rainsford, N.; Pasquier, C.; Bujan, L. Effect of acute Zika virus infection on mouse brain development. EMBO Rep. 2016, 17, 1766–1775.

(13) Kramer, L. D.; Shi, P. Y. A multiplex microsphere immunoassay for Zika virus diagnosis. EBioMedicine 2017, 16, 136–140.

(14) Mlakar, J.; Korva, M.; Tul, N.; Popovic, M.; Poljsak-Prijatelj, M.; Mraz, J.; Kolenc, M.; Rus, K. R.; Vipotnik, T. V.; Vodusek, V. F.; Virak, J.; Pizem, J.; Petrovec, M.; Zupanc, T. A. Zika Virus Associated with Microcephaly. N. Engl. J. Med. 2016, 374 (10), 951–958.

(15) Mlakar, J.; Korva, M.; Tul, N.; Popovic, M.; Poljsak-Prijatelj, M.; Mraz, J.; Kolenc, M.; Rus, K. R.; Vipotnik, T. V.; Vodusek, V. F.; Virak, J.; Pizem, J.; Petrovec, M.; Zupanc, T. A. Zika Virus Associated with Microcephaly. N. Engl. J. Med. 2016, 374 (10), 951–958.
between Zika virus and microcephaly in French Polynesia, 2013–15: a retrospective study. Lancet 2016, 387, 2125–2132.

(36) Bosch, I.; de Puig, H.; Hiley, M.; Carre-Camps, M.; Perdomo-Celis, F.; Narvaez, C. F.; Salgado, D. M.; Senthor, D.; O’Grady, M.; Phillips, E.; Durbin, A.; Fandos, D.; Miyazaki, H.; Yen, C.-W.; Géveloz-Ramirez, M.; Warke, R. V.; Ribeiro, L. S.; Teixeira, M. M.; Almeida, R. P.; Munoz-Medina, J. E.; Ludert, J. E.; Nogueira, M. L.; Colombo, T. E.; Terrizan, A. C. B.; Bozza, P. T.; Calheiros, A. S.; Vieira, Y. R.; Barbosa-Lima, G.; Vizzoni, A.; Cerbino-Neto, J.; Bozza, F. A.; Souza, T. M. L.; Trugilio, M. R. O.; de Filippis, A. M. B.; de Souza, P. C.; Marques, E. T. A.; Magalhaes, T.; Diaz, F. J.; Restrepo, B. N.; Marin, K.; Mattar, S.; Olson, D.; Asturias, E. J.; Lucera, M.; Singla, M.; Medigeshi, G. R.; de Bosch, N.; Tam, J.; Gomez-Marquez, J.; Clavet, C.; Villar, L.; Hamad-Schifferli, K.; Gehre, L. Rapid antigen tests for dengue virus serotypes and Zika virus in patient serum. Sci. Transl. Med. 2017, 9, eaan1589.

(37) Wen, J.; Tang, W. W.; Sheets, N.; Ellison, J.; Sette, A.; Kim, K.; Shresta, S. Identification of Zika virus epitopes reveals immunodominant and protective roles for dengue virus cross-reactive CD8+ T cells. Nat. Microbiol. 2017, 2, 17036.

(38) Bautista, L. E.; Sethi, A. K. Association between Guillian-Barre syndrome and Zika virus infection. Lancet 2016, 387, 2599–2600.

(39) Baptista, T.; Quaghebeur, G.; Alarcon, A. Neuroimaging findings of babies with microcephaly and presumed congenital Zika virus infection. Br. Med. J. 2016, 353, i2194.

(40) Besnard, M.; Lastere, S.; Teissier, A.; Cao-Lormeau, V.; Musso, D. Evidence of perinatal transmission of Zika virus, French Polynesia, December 2013 and February 2014. Euro Surveill. 2014, 19, 20751.

(41) Wahre, T.; Maaggard, A.; Tappe, D.; Cadar, D.; Schmidt-Chanasit, J. Zika virus infection after travel to Tahiti, December 2013. Emerging Infect. Dis. 2014, 20, 1412–1414.

(42) Lee, K. H.; Zeng, H. Apatser-Based ELISA assay for Highly Specific and Sensitive Detection of Zika NS1 Protein. Anal. Chem. 2017, 89, 12743–12748.

(43) Hage, D. S. Development of Immunochromatographic Assays for the Selective Detection of Zika Virus or Dengue Virus Serotypes in Serum. Clin. Chem. 2018, 64, 991–993.

(44) Ceccheto, J.; Fernandes, F. C. B.; Lopes, R.; Bueno, P. R. The capsid specific sensing of NS1 Flavivirus biomarker. Biosens. Bioelectron. 2017, 87, 949–956.

(45) Bedin, F.; Boulet, L.; Volin, E.; Theillet, G.; Rubens, A.; Rozand, C. Paper-based point-of-care testing for cost-effective diagnosis of acute flavivirus infections. J. Med. Virol. 2017, 89, 1520–1527.

(46) Eboigbodin, K. E.; Brummer, M.; Ojalehto, T.; Hoser, M. Rapid molecular diagnostic test for Zika virus with low demands on sample preparation and instrumentation. Diagn. Microbiol. Infect. Dis. 2016, 86, 369–371.

(47) Tian, B.; Qiu, Z.; Ma, J.; Zarzán Gómez de la Torre, T.; Johansson, C.; Svedling, P.; Strömberg, M. Attomolar Zika virus oligonucleotide detection based on loop-mediated isothermal amplification and AC susceptibility. Biosens. Bioelectron. 2016, 82, 420–425.

(48) Song, J.; Mauk, G. M.; Hackett, B. A.; Cherry, S.; Bau, H. H.; Liu, C. Instrument-Free Point of Care Molecular Detection of Zika Virus. Anal. Chem. 2016, 88, 7289–7294.

(49) Chotivan, N.; Brewster, C. D.; Magalhaes, T.; Weger-Lucarelli, J.; Duggal, N. K.; Rückert, C.; Nguyen, C.; Garcia Luna, S. M.; Fauser, J. R.; Andre, B.; Gray, M.; Black, W. C.; Kading, R. C.; Ebel, G. D.; Kuan, G.; Balmaseda, A.; Jaenisch, T.; Marques, E. T. A.; Brault, A. C.; Harris, E.; Foy, B. D.; Quackenbush, S. L.; Perera, R.; Rovnak, J. Rapid and specific detection of Asian- and African-lineage Zika viruses. Sci. Transl. Med. 2017, 9, eaao5038.

(50) Pardee, K.; Green, A. A.; Takahashi, M. K.; Braff, D.; Lambert, G.; Lee, J. W.; Santel, I.; Sabin, A.; Suarez, P. Microcephaly in Brazil. Lancet 2016, 387, 2125–2132.

(51) Caldas, S.; Besnard, M.; Bombard, P.; Dub, T.; Guillemette-Artur, P.; Eyrolle-Guignot, D.; Salje, H.; Van Kerkhove, M. D.; Abadie, V.; Garel, C.; Fontanet, A.; Mallet, H. P. Association
(S1) Lustig, Y.; Mendelson, E.; Paran, N.; Melamed, S.; Schwartz, E. Detection of Zika virus RNA in whole blood of imported Zika virus disease cases up to 2 months after symptom onset, Israel, December 2015 to April 2016. Euro Surveill 2016, 21, 30269.